Other ALK inhibitors are available for the treatment of ALK-positive NSCLC, including crizotinib, ceritinib, and brigatinib. Each of these medications has its own set of advantages and potential side effects. The choice of therapy depends on various factors, including the patient's medical history, previous treatments, and specific characteristics of their cancer.
